Journal
CURRENT DRUG TARGETS
Volume 15, Issue 7, Pages 689-702Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450115666140326094504
Keywords
Antibiotic; beta-lactam; inhibitor; metallo-beta-lactamase; resistant and zinc enzyme
Categories
Funding
- National Natural Science Foundation of China [20872081, 21072114]
- Natural Science Foundation of Shandong [ZR2010HM092]
- China-Australia Centre for Health Sciences Research (CACHSR) [2014GJ06]
Ask authors/readers for more resources
The overuse of antibiotics which exerts the selective pressure for bacterial pathogens has facilitated the spread of antibiotics' resistance. Metallo-beta-lactamases (M beta Ls) are zinc enzymes produced by an increasing number of bacterial pathogens. They can readily cleave carbapenems and most other beta-lactams that are mainstays of therapy for bacterial infections. M beta L-conferred resistance to antibiotics is most worrisome due to M beta Ls exhibiting very broad-spectrum resistance. Therefore, the bacteria carrying M beta Ls have recently become a significant clinical threat. No clinically useful M beta Ls inhibitor has been discovered yet. To address the serious threat to public health posed by the M beta L-conferred resistance to antibiotics, novel effective M beta L inhibitors are urgently needed. This review mainly describes various M beta L inhibitors, giving special attention to their antibacterial activity, mechanisms of action, structure-activity relationships and synergetic effect with clinically available antibiotics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available